Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats

Dig Dis Sci. 2013 Oct;58(10):2895-902. doi: 10.1007/s10620-013-2823-6. Epub 2013 Aug 23.

Abstract

Background and purpose: The underlying mechanisms of nonalcoholic steatohepatitis (NASH) are poorly understood, and little is known about hepatocellular apoptosis in NASH. Cyclooxygenase (COX)-2, the key enzyme in eicosanoid metabolism, is highly expressed in NASH. COX-2 can also regulate the release of mediators of inflammation, such as tumor necrosis factor (TNF)-α and interleukin (IL)-6. The aim of our study was to evaluate the effects of COX-2 on hepatocellular apoptosis and the mechanism of the action in the pathogenesis of NASH in rats.

Methods: Sprague-Dawley rats were fed a high-fat diet (HFD) or standard diet for 8 and 12 weeks. COX-2 and cytokines expression in hepatic tissue and TNF-α and IL-6 levels in serum were measured at 8 and 12 weeks. Moreover, celecoxib (10 mg/kg body weight once a day) was administered to rats for 4 weeks to inhibit the expression of COX-2. Liver pathology was assessed by hematoxylin and eosin (H&E) stain and electron microscopy. Hepatocyte apoptosis was evaluated by TUNEL staining.

Results: COX-2 messenger RNA and protein were highly expressed in livers of HFD rats and were correlated with the severity of steatohepatitis (R = 0.82, p < 0.01). COX-2 upregulation was preceded by increases in TNF-α and IL-6. The level of hepatocellular apoptosis was significantly higher in HFD rats than in the control rats. The hepatocellular apoptosis was suppressed by the inhibition of COX-2.

Conclusions: COX-2 may promote hepatocellular apoptosis by interacting with TNF-α and IL-6 in NASH in rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Celecoxib
  • Cyclooxygenase 2 / drug effects
  • Cyclooxygenase 2 / physiology*
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Diet, High-Fat / adverse effects
  • Disease Models, Animal
  • Fatty Liver / etiology*
  • Fatty Liver / pathology
  • Fatty Liver / physiopathology*
  • Hepatocytes / pathology*
  • Interleukin-6 / physiology*
  • Liver / drug effects
  • Liver / enzymology
  • Liver / pathology
  • Male
  • Non-alcoholic Fatty Liver Disease
  • Pyrazoles / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Severity of Illness Index
  • Sulfonamides / pharmacology
  • Tumor Necrosis Factor-alpha / physiology*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Interleukin-6
  • Pyrazoles
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
  • Cyclooxygenase 2
  • Celecoxib